Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit.
In the latest trading session, Boston Scientific (BSX) closed at $95.12, marking a -0.14% move from the previous day.
Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
In the latest trading session, Boston Scientific (BSX) closed at $93.67, marking a +1.11% move from the previous day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Boston Scientific (BSX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
Boston Scientific (BSX) reachead $100.88 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
Boston Scientific continues to successfully expand its operations across various geographies outside the United States.
Boston Scientific has the highest Composite Rating of 126 companies in the medical products industry. The post Medical Products Leader Tops These Early-Bird Buy Points appeared first on Investor's Business Daily.